New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
...ceuticals, Inc., Innogenetics NV, InterMune, Inc.,
intarcia Therapeutics, Inc., Medivir AB, Merck & Co., I...couraging Interim Results with Albuferon II-58
intarcia Releases Study Results of Omega Interferon II-58
...Belgium) II-73
InterMune, Inc. (USA) II-73
intarcia Therapeutics, Inc. (USA) II-74
Medivir AB (Swe...
Intarcia in Medical Technology
Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
...tes
HAYWARD, Calif., April 24 /PRNewswire/ --
intarcia Therapeutics, Inc. today announced the completion ...wscom.com/cgi-bin/prnh/20050301/SFTU126LOGO )
intarcia began the development of ITCA 650 in 2007 after ac...
ITCA 650 is the second DUROS delivery program
intarcia has moved into clinical development. In December 2...
Intarcia Therapeutics Announces Final Results From a Phase 2 Study
of Injectable Omega Interferon plus Ribavirin for the Treatment of
Hepatitis C Genotype-1
... subcutaneous omega interferon
injections provides
intarcia with safety and clinical response data
to support ... 6%
p= 0.001
With this study,
intarcia also took a step toward testing its
hypothesis tha...ogy
developed by ALZA Corporation, and licensed to
intarcia for use in
certain broad fields. Another product i...
Intarcia Therapeutics Announces Presentation of Final Results From
a Phase 2 Combination Study for the Treatment of Hepatitis C at the
Digestive Disease Week Conference
... therapy
WASHINGTON, May 21, 2007 /PRNewswire/ --
intarcia Therapeutics,
Inc., a privately held biopharmaceut... subcutaneous omega interferon
injections provides
intarcia with safety and clinical response data
to support ... 6 %
p= 0.001
With this study,
intarcia also took a step toward testing its
hypothesis tha...
Intarcia in Biological Technology
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
...treatment
NEW ORLEANS, June 8 /PRNewswire/ --
intarcia Therapeutics, Inc. today presented results from th...etes," said K. Alice Leung, President & CEO of
intarcia Therapeutics, Inc. "ITCA 650 ensures that patient...-injection therapy for type 2 diabetes.
About
intarcia
...
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
...betes
HAYWARD, Calif., May 27 /PRNewswire/ --
intarcia Therapeutics, Inc. today announced it will present...breaker," said Alice Leung, President & CEO of
intarcia Therapeutics, Inc. "Our team worked very hard to ...ce. Dr. Kenneth Luskey, VP, Clinical Research, at
intarcia will be available to answer questions on Saturday,...
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
... HAYWARD, Calif., Sept. 9 /PRNewswire/ --
intarcia Therapeutics, Inc.
today announced the appointment...etabolism.
"We are very pleased to have Ken join
intarcia Therapeutics to lead our
hepatitis C and diabetes ...pany's pipeline in the metabolic diseases area."
intarcia is currently conducting a phase 1 study of Omega D...